SVB Securities analyst Jonathan Chang downgraded Calithera Biosciences to Market Perform from Outperform with a price target of $2, down from $18.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CALA:
- Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
- Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
- Calithera Rises on Fast Track Designation for Sapanisertib
- Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer